Peptides for Body Composition: Recomp Protocols with CJC-1295, AOD-9604, and Tesamorelin

Body recomposition — simultaneously reducing fat and building lean muscle — is physiologically demanding and requires specific hormonal conditions that become harder to achieve naturally with age. Growth hormone and its downstream effector IGF-1 are central to this process, governing both lipolysis (fat breakdown) and anabolic signaling for muscle tissue.

Peptides that optimize GH axis function offer a targeted, safer alternative to exogenous HGH while producing meaningful body composition improvements. This guide covers the primary options, their mechanisms, and how to structure a recomposition protocol.

The Role of Growth Hormone in Body Composition

Growth hormone drives body composition through several mechanisms:

• Lipolysis: GH directly stimulates hormone-sensitive lipase (HSL) activity in fat cells, releasing stored triglycerides for energy — particularly in visceral and subcutaneous abdominal depots
• Protein synthesis: Through IGF-1, GH enhances amino acid uptake and muscle protein synthesis
• Substrate partitioning: GH shifts fuel preference toward fat oxidation, sparing muscle glycogen and protein
• Anti-inflammatory effects: GH reduces inflammatory cytokines that contribute to muscle catabolism and fat accumulation

After age 30, GH production declines roughly 14% per decade. By age 50, many people have GH levels 50–70% lower than in their 20s — a primary driver of the body composition changes people attribute simply to "getting older."

Peptides that restore physiological GH patterns address this root cause without the side effects of exogenous HGH administration.

CJC-1295 / Ipamorelin: The Foundation Stack

CJC-1295 is a GHRH (growth hormone-releasing hormone) analog that extends the half-life of GHRH stimulation, producing sustained pituitary GH secretion. Ipamorelin is a selective GHRP (growth hormone-releasing peptide) that amplifies GH pulses through the ghrelin receptor without raising cortisol or prolactin — the side effects that limited older GHRPs like GHRP-6.

Together, they create a synergistic pulse of GH that closely mimics youthful physiological patterns.

Body Composition Effects

In research and clinical practice, CJC-1295/ipamorelin has demonstrated:

• Fat reduction: Particularly visceral and subcutaneous abdominal fat, with typical reductions of 5–10% body fat over 3–6 months of consistent use in combination with appropriate nutrition and training
• Lean mass preservation and building: Improved nitrogen retention and IGF-1 levels support muscle protein synthesis — critical for the anabolic side of recomposition
• Sleep improvement: Better sleep quality independently improves body composition through insulin sensitivity, cortisol regulation, and appetite hormone normalization
• Recovery enhancement: Faster tissue repair means more productive training sessions and less time in a catabolic recovery state

For a complete protocol overview, see our CJC-1295 peptide guide.

Typical Protocol

CJC-1295 (without DAC, also called Mod GRF 1-29) at 100–200 mcg combined with ipamorelin at 100–200 mcg, administered subcutaneously 30–60 minutes before bed (to align with the natural nocturnal GH pulse), 5 days per week. A common cycle is 12 weeks on, 4 weeks off.

AOD-9604: Targeted Lipolysis Without GH Side Effects

AOD-9604 is a fragment of the HGH molecule (amino acids 176–191) that retains the lipolytic properties of GH without the growth-promoting effects on bone and other tissues. This makes it a more targeted tool for fat loss with a cleaner safety profile than full HGH.

Mechanism

AOD-9604 works through the beta-3 adrenergic receptor to stimulate lipolysis and inhibit lipogenesis (fat synthesis). Unlike exogenous HGH, it does not significantly raise IGF-1, does not cause hyperglycemia, and does not carry the growth-promoting risks associated with excess IGF-1.

In a series of clinical trials conducted by Metabolic Pharmaceuticals, AOD-9604 demonstrated:

• Statistically significant fat loss compared to placebo over 12–24 weeks
• Preferential reduction in abdominal fat
• Favorable safety profile with no significant metabolic disturbances

The trials were ultimately not pursued to full pharmaceutical approval for regulatory and commercial reasons, but the compound's safety and efficacy data remain noteworthy.

For more details on AOD-9604, see our AOD-9604 peptide guide.

Protocol

AOD-9604 is typically administered subcutaneously at 300–500 mcg per day, ideally in a fasted state in the morning (to maximize the lipolytic effect during a period of low insulin). It is often cycled at 8–12 weeks.

AOD-9604 vs. CJC-1295/Ipamorelin for Fat Loss

| Feature | AOD-9604 | CJC-1295/Ipamorelin | |---------|----------|---------------------| | Fat loss mechanism | Direct beta-3 adrenergic lipolysis | GH-mediated HSL activation | | Muscle support | Minimal | Strong (via IGF-1) | | Sleep improvement | Minimal | Significant | | IGF-1 elevation | Minimal | Moderate | | Best for | Pure fat loss focus | Full recomposition |

AOD-9604 is often added to a GH peptide stack when fat loss is the primary goal and the user is already satisfied with lean mass maintenance through training.

Tesamorelin: The Visceral Fat Specialist

Tesamorelin is a full-length GHRH analog that was FDA-approved for HIV-associated lipodystrophy — a condition characterized by pathological accumulation of visceral adipose tissue. Its approval for this indication established the strongest clinical evidence base of any body composition peptide.

Why Visceral Fat Matters

Visceral fat (fat around the organs in the abdominal cavity) is metabolically active in harmful ways — it releases inflammatory cytokines, disrupts insulin signaling, and is strongly associated with cardiovascular disease, type 2 diabetes, and accelerated aging. Subcutaneous fat (under the skin) is far less metabolically dangerous by comparison.

Tesamorelin specifically reduces visceral adipose tissue (VAT) by stimulating GH secretion in a sustained, physiological manner. Across multiple randomized controlled trials:

• Visceral fat reduced by 15–20% over 26 weeks versus placebo
• Triglycerides and inflammatory markers improved alongside fat reduction
• Effects were maintained with continued use

For a complete tesamorelin overview, see our tesamorelin peptide guide.

Who Benefits Most from Tesamorelin

Tesamorelin is particularly valuable for:

• Adults with disproportionate visceral fat accumulation despite healthy body weight
• Individuals with metabolic syndrome or elevated cardiovascular risk
• Those who have found subcutaneous fat responds well to training but visceral fat is stubborn

Typical Protocol

Tesamorelin is typically administered at 1–2 mg subcutaneously per day. In the clinical trials, once-daily dosing was used. Given its pedigree from clinical trials, tesamorelin has one of the most well-defined dosing protocols of any peptide discussed here.

Building a Recomposition Stack

A comprehensive peptide recomp protocol might combine:

1. CJC-1295/ipamorelin (before bed, 5x/week): Foundation for GH optimization, anabolic signaling, and sleep quality
2. AOD-9604 (morning, fasted): Additional fat-loss specificity targeting beta-3 adrenergic lipolysis
3. BPC-157 (optional): Accelerated recovery between training sessions to maximize training frequency and muscle-building stimulus — see our peptides for recovery speed guide

For intermediate and advanced practitioners, this stack can produce body composition changes that closely resemble the effects of low-dose exogenous HGH but with fewer side effects and a more favorable regulatory profile.

The Non-Negotiables: Diet and Training

No peptide stack overrides the fundamentals. For recomposition specifically:

• Protein intake: 1.6–2.2g per kg of body weight per day is required to support muscle protein synthesis, especially when in a caloric deficit
• Resistance training: The anabolic signaling from GH peptides requires a training stimulus to manifest as muscle. Resistance training at least 3x/week is essential
• Sleep: GH peptides particularly depend on nocturnal GH pulse quality. Protecting 7–9 hours of sleep is not optional

Our best peptides for body building guide covers the competitive and advanced training context for these compounds.

Frequently Asked Questions

Q: How long does it take to see body composition changes from peptides? Most people notice improved sleep and reduced water retention within 2–4 weeks. Meaningful changes in body fat and muscle mass typically become visible at 8–12 weeks, with the most significant effects at 3–6 months of consistent use.

Q: Can peptides replace the need for a caloric deficit for fat loss? Peptides enhance fat oxidation and lipolysis, but they do not entirely override energy balance. A modest caloric deficit combined with peptides typically produces the best fat loss results without compromising muscle preservation.

Q: Are these peptides safe for women? Yes, with appropriate dose adjustments. Women are often more sensitive to GH peptides and may find lower doses (50–100 mcg for ipamorelin/CJC-1295) sufficient. AOD-9604 and tesamorelin are also used in women. See our best peptides for women guide for female-specific considerations.

Q: Will I need to cycle off body composition peptides? GH peptides are typically cycled (12 weeks on, 4 weeks off) to maintain pituitary sensitivity. AOD-9604 can be cycled similarly or used continuously in the short term. Cycling also allows assessment of sustained results.

Q: Can these peptides cause diabetes or insulin resistance? GH has known effects on insulin sensitivity, and high-dose exogenous HGH can cause insulin resistance. Peptides that stimulate physiological GH pulses are generally much less likely to cause these effects, but monitoring fasting glucose periodically during longer-term use is prudent.